Mean | Std. Dev | F | Sig | Tukey test | ||
---|---|---|---|---|---|---|
E/I ratio | Control | 1.2660 | 0.06073 | 4.724 | 0.013 | P1:0.661 P2:0.011 P3:0.094 |
Drug-naïve patients with PD | 1.2385 | 0.08087 | ||||
Patients with PD on dopaminergic drugs | 1.1705 | 0.14307 | ||||
Valsalva ratio | Control | 1.2805 | 0.03804 | 6.518 | 0.003 | P1: 0.603 P2:0.003 P3: 0.037 |
Drug-naïve patients with PD | 1.2480 | 0.09197 | ||||
Patients with PD on dopaminergic drugs | 1.1625 | 0.15586 | ||||
30:15 ratio | Control | 1.0795 | 0.02350 | 8.294 | 0.001 | P1:0.748 P2: 0.008 P3:0.001 |
Drug-naive | 1.0585 | 0.04603 | ||||
Patients with PD on dopaminergic drugs | 1.1690 | 0.14913 | ||||
CSP (median sensory n) onset latency | Control | 76.2000 | 2.33057 | 7.843 | 0.001 | P1: 0.542 P2:0.001 P3:0.020 |
Drug-naïve patients with PD | 78.5500 | 5.46255 | ||||
Patients with PD on dopaminergic drugs | 84.7000 | 10.58847 | ||||
CSP (median sensory n) duration | Control | 44.2500 | 2.97135 | 1.862 | 0.165 | P1:1.00 P2:0.230 P3: 0.220 |
Drug-naïve patients with PD | 44.3000 | 4.84605 | ||||
Patients with PD on dopaminergic drugs | 41.3000 | 7.92132 | ||||
CSP (sural nerve) onset latency | Control | 94.7500 | 2.46822 | 12.034 | 0.001 | P1:0.853 P2: 0.001 P3:0.001 |
Drug-naïve patients with PD | 96.1500 | 7.69330 | ||||
Patients with PD on dopaminergic drugs | 106.4500 | 11.75842 | ||||
CSP (sural n) duration | control | 46.8500 | 2.79614 | 4.443 | 0.016 | P1:0.275 P2: 0.012 P3:0.335 |
Drug-naïve patients with PD | 43.8000 | 5.53078 | ||||
Patients with PD on dopaminergic drugs | 41.0000 | 8.80191 | ||||
SSR (Palm)sec | Control | 1.2250 | .08507 | 4.313 | 0.018 | P1:0.528 P2: 0.014 P3:0.173 |
Drug-naïve patients with PD | 1.3350 | .21343 | ||||
Patients with PD on dopaminergic drugs | 1.5200 | .50638 | ||||
SSR (Sole) sec | Control | 1.5500 | .14327 | 13.646 | 0.001 | P1:0.001 P2: 0.001 P3:0.395 |
Drug-naïve patients with PD | 2.0050 | .36631 | ||||
Patients with PD on dopaminergic drugs | 2.1650 | .54122 | ||||
Systolic blood pressure to active standing(mmHg) | Control | 9.4000 | 1.09545 | 152.879 | 0.001 | P1:0.415 P2:0.001 P3:0.001 |
Drug-naïve patients with PD | 11.1500 | 7.43587 | ||||
Patients with PD on dopaminergic drugs | 31.0000 | 0.00000 | ||||
Diastolic blood pressure response to sustained hand grip (mmHg) | Control | 18.0000 | 0.000 | 5.980 | 0.004 | P1:0.039 P2: 0.004 P3:0.679 |
Drug-naïve patients with PD | 15.3550 | 4.32672 | ||||
Patients with PD on dopaminergic drugs | 14.5000 | 3.83200 | ||||
SSR amplitude (mv) palm | Control | 1.2000 | 0.000 | 10.750 | 0.001 | P1:0.945 P2:0.001 P3: 0.001 |
Drug-naïve patients with PD | 1.1800 | 0.15079 | ||||
Patients with PD on dopaminergic drugs | 0.9400 | 0.30677 | ||||
SSR amplitude (mv) sole | Control | 0.3550 | 0.06863 | 52.916 | 0.001 | P1:0.001 P2:0.001 P3: 0.113 |
Drug-naïve patients with PD | 0.2260 | 0.04988 | ||||
Patients with PD on dopaminergic drugs | 0.1920 | 0.03443 | ||||
Ewing score | Control | 0.1000 | 0.20520 | 2.784 | 0.071 | P1:0.760 P2:0.060 P3:0.029 |
Drug-naïve patients with PD | 0.5000 | 1.53897 | ||||
Patients with PD on dopaminergic drugs | 1.2500 | 2.22131 |